Kinetics and Prediction of HBsAg Loss during Long-Term Therapy with Nucleos(t)ide Analogues of Different Potency in Patients with Chronic Hepatitis B

BACKGROUND & AIMS: About 350–400 million people are infected with hepatitis B virus (HBV) chronically and 1 million people die of hepatitis B virus (HBV)-related liver diseases. Nucleos(t)ide analogues (NAs) have been used for the treatment against HBV. However, few studies have investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Min-Ran, Xi, Hong-Li, Wang, Qin-Huan, Hou, Feng-Qin, Huo, Na, Zhang, Xia-Xia, Li, Fang, Xu, Xiao-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048200/
https://www.ncbi.nlm.nih.gov/pubmed/24905586
http://dx.doi.org/10.1371/journal.pone.0098476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048200/
https://www.ncbi.nlm.nih.gov/pubmed/24905586
http://dx.doi.org/10.1371/journal.pone.0098476

Ejemplares similares